Pitfalls of cell therapy manufacturing IP - A case study (T 0868/23)

The recent Board of Appeal decision in T 0868/23 is a powerful example of the potential fragility of process IP in the field of cell therapy. The decision in T 0868/23 illustrates how a cell therapy process invention may evolve over time to the detriment of the IP. Processes can be notoriously difficult to pin down, leaving even seemingly broad claims vulnerable to attack in the